Literature DB >> 14609246

Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia.

Aileen B Rothbard1, Eri Kuno, Kathy Foley.   

Abstract

This article examines trends in antipsychotic medication use in a treated population of publicly funded patients with schizophrenia between 1991 and 1996. Findings from administrative claims data show that antipsychotic prescription rates increased from 79 percent to 83 percent between 1991 and 1996. Atypical antipsychotics were used by 39 percent of the population and comprised 41 percent of all antipsychotic agents prescribed compared to 59 percent for typical agents. Duration on a typical agent was 8 months versus 7.4 months for newer atypicals, with duration 11 months for those on clozapine. The highest switching behavior is found in users of atypicals (58% versus 25% for those on typicals) as is the percent of those who received an antidepressant concurrently with an antipsychotic, which was 44 percent for newer atypical users versus 31 percent for typical users. The lowest antidepressant use was among clozapine users (28%). Atypical users were more likely to be younger Caucasian men with higher use of inpatient and ambulatory mental health services compared to those on typical medications. The newer antipsychotic medications appear to be displacing traditional medications; however, contrary to what the literature suggests, duration is shorter and switching behavior and concurrent use of antidepressants is higher than in typical users.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609246     DOI: 10.1093/oxfordjournals.schbul.a007025

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  15 in total

1.  Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Authors:  Y-T Xiang; G S Ungvari; C U Correll; H F K Chiu; N Shinfuku
Journal:  Epidemiol Psychiatr Sci       Date:  2015-08-20       Impact factor: 6.892

2.  Drug treatment modalities in psychiatric inpatient practice: a 20-year comparison.

Authors:  Corrado Barbui; Arcangelo Ciuna; Michela Nosè; Deborah Levi; Margherita Andretta; Scott B Patten; Francesco Amaddeo; Michele Tansella
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

Review 3.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

4.  Communities of color? Client-to-client racial concordance in the selection of mental health programs for Caucasians and African Americans.

Authors:  Naoru Koizumi; Aileen B Rothbard; Tony E Smith; Jeremy D Mayer
Journal:  Health Care Manag Sci       Date:  2011-05-25

5.  The effect of income and race on quality of psychiatric care in community mental health centers.

Authors:  Eri Kuno; Aileen B Rothbard
Journal:  Community Ment Health J       Date:  2005-10

6.  Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study.

Authors:  Chi-Un Pae; Alberto Chiesa; Laura Mandelli; Ashwin A Patkar; Sara Gibiino; Alessandro Serretti
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004.

Authors:  Tiemo Wessels; Dandy Grünler; Christa Bunk; Michael Specka; Markus Gastpar; Norbert Scherbaum; Eugen Davids
Journal:  Psychiatr Q       Date:  2007-06

8.  The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.

Authors:  Marcela Horvitz-Lennon; Julie M Donohue; Judith R Lave; Margarita Alegría; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2013-03-01       Impact factor: 3.084

Review 9.  Polypharmacy for schizophrenia.

Authors:  Jacob Ballon; T Scott Stroup
Journal:  Curr Opin Psychiatry       Date:  2013-03       Impact factor: 4.741

10.  Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.

Authors:  Mark Olfson; Steven C Marcus; Haya Ascher-Svanum
Journal:  Schizophr Bull       Date:  2007-04-29       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.